Head to Head Review: Nordic Nanovector ASA (OTCMKTS:NRNVF) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Nordic Nanovector ASA (OTCMKTS:NRNVF) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Profitability

This table compares BioCryst Pharmaceuticals and Nordic Nanovector ASA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Nordic Nanovector ASA	N/A	N/A	N/A

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Nordic Nanovector ASA”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	2.79	$263.86 million	($1.50)	-6.37
Nordic Nanovector ASA	N/A	N/A	N/A	N/A	N/A

BioCryst Pharmaceuticals has higher revenue and earnings than Nordic Nanovector ASA.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Nordic Nanovector ASA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	4	8	0	2.67
Nordic Nanovector ASA	0	0	0	0	0.00

BioCryst Pharmaceuticals currently has a consensus target price of $20.60, indicating a potential upside of 115.48%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Nordic Nanovector ASA.

Summary

BioCryst Pharmaceuticals beats Nordic Nanovector ASA on 7 of the 9 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.